Möchten Sie immer auf dem neuesten Stand bleiben?

OSE Immunotherapeutics annonce des résultats positifs d'efficacité de Lusvertikimab dans l'essai clinique de phase 2 pour le traitement de la rectocolite hémorragique Lusvertikimab démontre une...

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis Lusvertikimab demonstrates significant efficacy during the...

London, England, July 24, 2024 (GLOBE NEWSWIRE) -- Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (RSV) for older adults in the US from $4.7bn per year...

NANTERRE (FRANCE)JULY 24, 2024 H1 2024 RESULTS IMPROVED YEAR-ON-YEAR PERFORMANCE CONFIRMED FY 2024 GUIDANCE, WITH SALES AND OPERATING MARGIN NOW EXPECTED IN THE LOWER END OF THE RANGE CONFIRMED...

  +6% organic growth and strong financial performance led by Electrification businesses in H1 2024 2024 guidance upgraded _PRESS RELEASE_ H1 2024...

PHILADELPHIA, July 23, 2024 (GLOBE NEWSWIRE) -- Brandywine Realty Trust (NYSE: BDN) today reported its financial and operating results for the three and six-month periods ended June 30, 2024. ...

FORT WORTH, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced its second quarter 2024 financial results. Second Quarter 2024 Highlights – Cash...

SAN FRANCISCO, July 23, 2024 (GLOBE NEWSWIRE) -- Kubecost, the comprehensive solution for monitoring, managing, and optimizing Kubernetes spend at scale, today announced it has surpassed 10 million...

Good results for Christian Dior in the first half of the year despite the prevailing environment Paris, July 23, 2024 The Christian Dior Group recorded revenue of €41.7 billion in the first half of...

  Alstom’s first quarter 2024/25: deleveraging plan delivered, Q1 orders and sales in line with FY 2024/25 trajectory, outlook confirmed Hybrid issuance and rights issue fully executed, closing of...